Journal article
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
E Bachy, MJ Maurer, TM Habermann, B Gelas-Dore, D Maucort-Boulch, JA Estell, E Van den Neste, R Bouabdallah, E Gyan, AL Feldman, J Bargay, A Delmer, SL Slager, MG da Silva, O Fitoussi, D Belada, H Maisonneuve, T Intragumtornchai, SM Ansell, T Lamy Show all
Blood | Published : 2018
Abstract
In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of patients treated with initial immunochemotherapy. There is currently a need to define parsimonious clinical models for trial stratification and to add on biomolecular factors. Here, we confirmed the validity of both the follicular lymphoma international prognostic index (FLIPI) and the FLIPI2 in the large prospective PRIMA trial cohort of 1135 patients treated with initial R-chemotherapy 6 R maintenance. Furthermore, we developed a new prognostic tool comprising only 2 simple parameters (bone marrow involvement and b2-microglobulin [b2m]) to predict progression-free survival (PFS). The final simplifie..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
E.B. has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie (grant agreement 661106); the Philippe Foundation; and the Fulbright Program (Monahan Foundation). The MER was supported by the National Institutes of Health, National Cancer Institute grants P50 CA97274 and U01 CA195568.